Tango Therapeutics, Inc. (TNGX) Form 10-Q — Aug 11, 2026
Tango Therapeutics reported a Q2 2026 net loss of $55.3 million, widened from $38.9 million a year earlier, with collaboration revenue of zero after the Gilead research term concluded in August 2025. The company held approximately $1.0 billion in cash and marketable securities at June 30, 2026, which management says funds operations for at least twelve months. The quarter's scientific centerpiece was the June 2026 disclosure of vopimetostat plus Revolution Medicines' daraxonrasib in MTAP-deleted pancreatic cancer, showing a 92% objective response rate (11 of 12 patients), 90% six-month progression-free survival, and 100% disease control rate.
Key figures
- Revenue
- 0
- Total Assets
- 1073880000
- Cash Position
- $1.0 billion (cash, cash equivalents and marketable securities; $345.6M cash and equivalents + $668.4M marketable securities)
- Shares Outstanding
- 168610367
- Six month eps
- -$0.68
- Total liabilities
- $49.3M
- Q2 2026 ga expense
- $22.6M (vs $11.3M year-ago)
- Q2 2026 rd expense
- $37.2M (vs $32.8M year-ago)
- Six month net loss
- $100.9M (vs $78.7M year-ago)
- Accumulated deficit
- $704.0M
- Atm remaining capacity
- $35.6M
- Atm gross proceeds h1 2026
- $64.4M (5,148,151 shares under Leerink Sales Agreement)
- Weighted avg shares q2 2026
- 149875939
- Gilead milestone eligibility
- up to $300.0M per program
- June 2026 offering net proceeds
- $651.4M
- Six month pfs pdac daraxonrasib
- 90%
- Oct 2025 offering gross proceeds
- $225.0M (22,755,438 shares at $8.66 plus pre-funded warrants)
- June 2026 offering gross proceeds
- $690.0M (21,166,676 shares at $30.00 plus 1,833,395 pre-funded warrants at $29.999)
- Orr pdac vopimetostat plus zoldonrasib
- 52% (27 response-evaluable patients)
- Orr pdac vopimetostat plus daraxonrasib
- 92% (11 of 12 patients, nine confirmed)
- Aggregate capital raised since inception
- $1.8B
- Orr nsclc vopimetostat plus daraxonrasib
- 100% (3 of 3 patients)
Price after filing
Close on the filing date to close N calendar days later (from $27.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.